SMS001

Phase 2Small molecule

TToLymph Inc.

SMS001 is one of 49 small molecule programs targeting Carcinoma, Non-Small-Cell Lung. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carcinoma, Non-Small-Cell LungRecruiting

Carcinoma, Non-Small-Cell LungPhase 2

Recruiting

Competition

Competitive Landscape

53 competitors in Carcinoma, Non-Small-Cell Lung

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

14 2

Rybrevant

Johnson & Johnson

Phase 3

13 3

Lazcluze

Johnson & Johnson

Phase 3

8 4

Imfinzi

AstraZeneca

Phase 3

7 5

Taxol

Teva

Phase 3

4 6

Paraplatin

AAvyxa

Phase 3

16 7

Tagrisso

AstraZeneca

Phase 3

3 8

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

13 9

Alimta

Rozlytrek

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06693336

Clinical

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung1 trial

Phase IIa Trial Evaluating the Safety and Therapeutic Effect of SMS001 as an Adjuvant Therapy to Control Tumor Recurrence in Stage Ib-IIIa (N2) Non-Small Cell Lung Cancer (NSCLC) Patients

Recruiting·TToLymph Inc.·Phase 2·NCT06693336·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SMS001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SMS001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SMS001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ToLymph Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TToLymph Inc.

SMS001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News